Coegin Pharma AB

NGM:COEGIN Stock Report

Market Cap: SEK 82.6m

Coegin Pharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Jens Eriksson

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.3yrs
CEO ownershipn/a
Management average tenure2.7yrs
Board average tenure2.2yrs

Recent management updates

Recent updates

CEO

Jens Eriksson (49 yo)

1.3yrs

Tenure

Mr. Jens Eriksson serves as Director at Coegin Pharma AB since October 2023 and serves its as Chief Executive Officer since April 2024 and served as Acting Chief Executive Officer since October 2023 until...

Leadership Team

NamePositionTenureCompensationOwnership
Jens Eriksson
CEO & Director1.3yrsno datano data
Lars Rasmussen
Chief Financial Officer2.8yrsno data0.15%
SEK 124.5k
John Zibert
Chief Medical Officer2.7yrsno data0.085%
SEK 70.6k

2.7yrs

Average Tenure

49yo

Average Age

Experienced Management: COEGIN's management team is considered experienced (2.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jens Eriksson
CEO & Director1.7yrsno datano data
Edward Dennis
Member of Scientific Advisory Boardno datano datano data
Joseph Bonventre
Member of Scientific Advisory Boardno datano datano data
Erlend Skagseth
Director4.3yrsno datano data
Thoas Fioretos
Director2.7yrsno datano data
George Kokotos
Member of Scientific Advisory Boardno datano datano data
J. Jongejan
Member of Scientific Advisory Boardno datano datano data
Jorgen Serup
Member of Scientific Advisory Boardno datano datano data
Eva Saers
Chairman of the Board1.7yrsno datano data

2.2yrs

Average Tenure

65.5yo

Average Age

Experienced Board: COEGIN's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 07:51
End of Day Share Price 2025/01/03 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Coegin Pharma AB is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kevin SuleRedeye